These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35532260)

  • 1. CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis.
    Chambers C; Quan L; Yi G; Esquela-Kerscher A
    J Vis Exp; 2022 Apr; (182):. PubMed ID: 35532260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
    Yang J; Meng X; Pan J; Jiang N; Zhou C; Wu Z; Gong Z
    RNA Biol; 2018 Jan; 15(1):35-43. PubMed ID: 29028415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrogation of Functional miRNA-Target Interactions by CRISPR/Cas9 Genome Engineering.
    Michaels YS; Wu Q; Fulga TA
    Methods Mol Biol; 2017; 1580():79-97. PubMed ID: 28439828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Approaches to Pinpoint Function within the Noncoding Genome.
    Montalbano A; Canver MC; Sanjana NE
    Mol Cell; 2017 Oct; 68(1):44-59. PubMed ID: 28985510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-Mediated Knockout of MicroRNA-744 Improves Antibody Titer of CHO Production Cell Lines.
    Raab N; Mathias S; Alt K; Handrick R; Fischer S; Schmieder V; Jadhav V; Borth N; Otte K
    Biotechnol J; 2019 May; 14(5):e1800477. PubMed ID: 30802343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
    Berkhout B; Gao Z; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR as a strong gene editing tool.
    Shen S; Loh TJ; Shen H; Zheng X; Shen H
    BMB Rep; 2017 Jan; 50(1):20-24. PubMed ID: 27616359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Robust Protocol for CRISPR-Cas9 Gene Editing in Human Suspension Cell Lines.
    Wardyn JD; Chan ASY; Jeyasekharan AD
    Curr Protoc; 2021 Nov; 1(11):e286. PubMed ID: 34748280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9.
    Yumlu S; Stumm J; Bashir S; Dreyer AK; Lisowski P; Danner E; Kühn R
    Methods; 2017 May; 121-122():29-44. PubMed ID: 28522326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric DNA-RNA Guide RNA Designs.
    Lu S; Zhang Y; Yin H
    Methods Mol Biol; 2021; 2162():79-85. PubMed ID: 32926379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic applications and therapeutic option of Cascade CRISPR/Cas in the modulation of miRNA in diverse cancers: promises and obstacles.
    Alinejad T; Modarressi S; Sadri Z; Hao Z; Chen CS
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):9557-9575. PubMed ID: 37222810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research.
    Aquino-Jarquin G
    Cancer Res; 2017 Dec; 77(24):6812-6817. PubMed ID: 29208606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional Control of CRISPR/Cas9 Function.
    Zhou W; Deiters A
    Angew Chem Int Ed Engl; 2016 Apr; 55(18):5394-9. PubMed ID: 26996256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A robust method for protein depletion based on gene editing.
    Yang Y; Wu W; Liu T; Dong L; Lei H
    Methods; 2021 Oct; 194():3-11. PubMed ID: 33705859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-Penetrating Peptide-Mediated Delivery of Cas9 Protein and Guide RNA for Genome Editing.
    Suresh B; Ramakrishna S; Kim H
    Methods Mol Biol; 2017; 1507():81-94. PubMed ID: 27832534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic CRISPR RNA-Cas9-guided genome editing in human cells.
    Rahdar M; McMahon MA; Prakash TP; Swayze EE; Bennett CF; Cleveland DW
    Proc Natl Acad Sci U S A; 2015 Dec; 112(51):E7110-7. PubMed ID: 26589814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.